Cancer immunoediting and resistance to T cell-based immunotherapyJake S. O’Donnell(The University of Queensland), Michele W.L. Teng(The University of Queensland), Mark J. Smyth(The University of Queensland)Nature Reviews Clinical OncologyDecember 6, 201810.1038/s41571-018-0142-8Cited by 1,779SaveCiteExport RISWatch citationsAbstractRelated PapersPD-1 Blockade in Tumors with Mismatch-Repair DeficiencyDung T. Le, Jennifer N. Uram, Hao Wang et al.|New England Journal of Medicine|2015|9.4kCancer immunotherapy: moving beyond current vaccinesSteven A. Rosenberg, James C. Yang, Nicholas P. Restifo|Nature Medicine|2004|3kMelanoma-intrinsic β-catenin signalling prevents anti-tumour immunityStefani Spranger, Riyue Bao, Thomas F. Gajewski|Nature|2015|2.8kAdoptive cell transfer as personalized immunotherapy for human cancerSteven A. Rosenberg, Nicholas P. Restifo|Science|2015|2.5kDirect Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and ImmunityLeticia Corrales, Laura Hix Glickman, Sarah M. McWhirter et al.|Cell Reports|2015|1.5k